For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Claudin18.2 is out, but the US big pharma opts in to a new project.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Questions continue to swirl as the unit mulls another oncology makeover.
